Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma

NCT04856189 is registered in ClinicalTrials.gov with Mamta Parikh as lead sponsor.

NCT NCT04856189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04856189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma
Lead sponsor
Mamta Parikh
Phase
Phase 1/2
Overall status
Terminated
Start date
April 8, 2021
Completion date
February 13, 2024
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced urothelial carcinoma, locally advanced urothelial carcinoma, metastatic urothelial carcinoma, refractory urothelial carcinoma